BRD9 and thrombocytosis disease: Near-complete abrogation of megakaryocytic lineage in the absence of BRD9 and accelerated terminal myeloid differentiation could theoretically be useful in managing pathologic conditions of megakaryocytic hyperactivity, such as essential thrombocythemia or other disorders associated with thrombocytosis.